Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 9:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sham capsule Clear all
Completed Phase 3 Interventional Results available

Secondary Prevention of Venous Thrombo Embolism (VTE).

NCT00329238
View directory record Official record
Conditions
Thromboembolism
Interventions
Dabigatran, Warfarin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,867 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
18
States / cities
Mobile, Alabama • Hartford, Connecticut • Clearwater, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced Sep 17, 2026, 9:04 AM EDT
Completed Not applicable Interventional Results available

A Study to Assess the Efficacy and Safety of the Vibrant Capsule Administered 5 Times Per Week

NCT03031301
View directory record Official record
Conditions
Constipation
Interventions
Vibrant capsule, Sham capsule
Device
Lead sponsor
Vibrant Ltd.
Industry
Eligibility
22 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Guntersville, Alabama • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 17, 2026, 9:04 AM EDT
Completed Phase 4 Interventional Results available

CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat

NCT02579096
View directory record Official record
Conditions
Gout, Chronic Kidney Diseases
Interventions
allopurinol capsule, 100-800 mg by mouth once daily, febuxostat tablet 40-120 mg by mouth once daily, Placebo, vehicle control (febuxostat-shaped), Placebo, vehicle control (allopurinol-shaped)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
23
States / cities
Loma Linda, California • San Diego, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Sep 17, 2026, 9:04 AM EDT
Completed Not applicable Interventional

Performance, Efficacy and Safety of Vibrating Capsule in Aiding Constipated Individuals

NCT02030756
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
vibrating capsule, sham non-vibrating capsule
Device
Lead sponsor
Vibrant Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chevy Chase, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Sep 17, 2026, 9:04 AM EDT
Recruiting Phase 2 Interventional

A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema

NCT07812090
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
Oral BGE-102, Oral Placebo Matching BGE-102, Anti-VEGF, Sham
Drug · Other
Lead sponsor
BioAge Labs, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 17, 2026, 9:04 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

NCT04373317
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
Pimavanserin, Quetiapine
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
358 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
24
States / cities
Tucson, Arizona • Loma Linda, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 17, 2026, 9:04 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Diesel Exhaust and Vascular Function

NCT01508637
View directory record Official record
Conditions
Cardiovascular Effects
Interventions
Diesel Exhaust, Filtered Air, Terazosin, placebo
Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 49 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 2, 2015 · Synced Sep 17, 2026, 9:04 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

An Innovative Intervention for OUD Treatment

NCT04325659
View directory record Official record
Conditions
Opioid-Related Disorders, Opioid Dependence, Opioid Addiction, Opioid Withdrawal
Interventions
Bridge Device, Lofexidine, Placebo, Sham Bridge Device
Device · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 17, 2026, 9:04 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy, Safety, and Tolerability of TC-5619 in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)

NCT01124708
View directory record Official record
Conditions
ADHD
Interventions
TC-5619-238, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
16
States / cities
Bradenton, Florida • Jacksonville, Florida • Lauderhill, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Sep 17, 2026, 9:04 AM EDT
Recruiting Phase 2 Interventional

Psilocybin rTMS for Treatment Resistant Depression

NCT06132178
View directory record Official record
Conditions
Treatment Resistant Depression, MDD, Major Depressive Disorder, Recurrent Depression, Depression
Interventions
Psilocybin, Accelerated intermittent theta burst (aiTBS) rTMS treatment, Low-dose psilocybin, Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment
Drug · Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
22 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 17, 2026, 9:04 AM EDT
Not yet recruiting Phase 2 Interventional

Effects of Pharmacological Stress and rTMS on Executive Function in Opioid Use Disorder

NCT04231708
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Yohimbine + Hydrocortisone, Active rTMS, Placebo, Sham rTMS
Drug · Device
Lead sponsor
Wayne State University
Other
Eligibility
21 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 17, 2026, 9:04 AM EDT
Not listed Phase 4 Interventional Results available

Effectiveness of Deep Brain Stimulation for Treating People With Treatment Resistant Obsessive-Compulsive Disorder

NCT00640133
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Active DBS, Sham DBS
Device
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2024
U.S. locations
9
States / cities
Redwood City, California • Washington D.C., District of Columbia • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Sep 17, 2026, 9:04 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Caffeine and Intermittent Hypoxia on Leg Function in Human Spinal Cord Injury

NCT02323698
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Caffeine, AIH, Placebo, SHAM
Drug · Other
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 17, 2026, 9:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Pyridostigmine for Constipation in Diabetics

NCT00276406
View directory record Official record
Conditions
Constipation, Diabetes Mellitus, Colonic Transit, Gastric Emptying
Interventions
Pyridostigmine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2012 · Synced Sep 17, 2026, 9:04 AM EDT
Recruiting Phase 2 Interventional

Effect of FB301 on Vaginal Bacterial Profile in Women With Asymptomatic Vaginal Dysbiosis Undergoing a Mock Frozen Embryo Transfer Cycle

NCT07453069
View directory record Official record
Conditions
Vaginal Dysbiosis
Interventions
FB-301, Placebo, Chlorhexidine (0.5%) Vaginal Cleanse, Sham vaginal cleanse (saline)
Drug · Other
Lead sponsor
Freya Biosciences ApS
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Wichita, Kansas • Waltham, Massachusetts • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 17, 2026, 9:04 AM EDT
Not listed Phase 4 Interventional

IPACK on Early Pain Scores After ACL Reconstruction

NCT05985629
View directory record Official record
Conditions
Pain, Postoperative, Anterior Cruciate Ligament Injuries, Analgesics, Opioid
Interventions
IPACK, PLACEBO
Drug
Lead sponsor
Loyola University
Other
Eligibility
16 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 17, 2026, 9:04 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)

NCT07221565
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases, Chronic Inflammatory Syndromes, Immune Dysregulation
Interventions
Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Sham Resonance Device (Inactive Control), Low-Dose Naltrexone (LDN)
Device · Drug
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 17, 2026, 9:04 AM EDT
Recruiting Early Phase 1 Interventional

Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression

NCT07560878
View directory record Official record
Conditions
Major Depression
Interventions
D-Cycloserine (DCS), Continuous theta-burst stimulation (cTBS), Transcranial Magnetic Stimulation Sham, Memantine, Lorazepam (drug), Baclofen, Placebo
Drug · Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 17, 2026, 9:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Estrogen and Serotonin on Changing Brain Chemistry

NCT01208324
View directory record Official record
Conditions
Menopause
Interventions
estrogen patch, Amino acids, Placebo Patch, Placebo pills
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
48 Years to 60 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Sep 17, 2026, 9:04 AM EDT
Completed Not applicable Interventional Results available

Feasibility of Placing Bravo PH Capsule in Proximal Esophagus

NCT00378898
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
BRAVO capsule, Fluoroscopy, sham BRAVO capsule placement
Device · Procedure · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 17, 2026, 9:04 AM EDT
Completed Phase 2Phase 3 Interventional

Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea

NCT03185143
View directory record Official record
Conditions
Migraine With and Without Aura
Interventions
Naltrexone and Acetaminophen Combination, Sumatriptan 100 mg, Placebo
Drug
Lead sponsor
Allodynic Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
North Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Sep 17, 2026, 9:04 AM EDT
Terminated Not applicable Interventional Results available

Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis

NCT01094717
View directory record Official record
Conditions
Psoriasis
Interventions
Acitretin 25Mg Oral Capsule, Excimer laser, Tazarotene 0.1% Gel,Top, Sham excimer laser
Drug · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Sep 17, 2026, 9:04 AM EDT
Terminated Not applicable Interventional Results available

Optimization of Synvisc-One for Knee OA

NCT02029703
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Synvisc-One Injection, Sham Injection
Device · Other
Lead sponsor
Elaine Husni
Other
Eligibility
21 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Sep 17, 2026, 9:04 AM EDT
Completed Early Phase 1 Interventional Results available

Neural Mechanisms of Cannabinoid-impaired Decision-Making in Emerging Adults

NCT03944954
View directory record Official record
Conditions
Neurosciences, Substance-Related Disorders, Behavior Problem
Interventions
Placebo TMS Sham, Marinol 10Mg Capsule TMS Sham, Marinol 30Mg Capsule TMS Sham, Placebo TMS Real, Marinol 10Mg Capsule TMS Real, Marinol 30Mg Capsule TMS Real
Device · Drug · Other
Lead sponsor
Michael J. Wesley, PhD
Other
Eligibility
18 Years to 34 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Sep 17, 2026, 9:04 AM EDT